Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 11

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

340

HTML

3663

Tables (1-3)

248

Sum=4251

Mar 21, 2005 (publication date) through Dec 12, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Reports

World J Gastroenterol. Mar 21, 2005; 11(11): 1629-1633
Published online Mar 21, 2005. doi: 10.3748/wjg.v11.i11.1629

Table 2 Intention-to-treat and per protocol cure rates of H pylori infection.

¹See Table 1 for the definition of each group. Patients received the medications for 7 d in each group;

²CI: Confidence intervals.

Citation: Isomoto H, Furusu H, Ohnita K, Wen CY, Inoue K, Kohno S. Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. World J Gastroenterol 2005; 11(11): 1629-1633
URL: https://www.wjgnet.com/1007-9327/full/v11/i11/1629.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i11.1629